Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-07-04

AUTHORS

Amy Puenpatom, Michael Hull, Jeffrey McPheeters, Kay Schwebke

ABSTRACT

IntroductionLedipasvir/sofosbuvir (LDV/SOF) for hepatitis C virus (HCV) treatment provides an oral interferon-free treatment regimen with high rates of sustained virologic response (SVR). This study assessed treatment discontinuation, factors associated with treatment completion, and real-world effectiveness.MethodsPatients with HCV treated with LDV/SOF between October 2014 and June 2015 and enrolled in a large US health plan were identified. Expected treatment duration was calculated based on IDSA/AASLD treatment guidelines and US labels using data for genotype, initial treatment regimen, baseline cirrhosis, and prior treatments. Logistic regression was used to identify factors associated with treatment completion, controlling for patient characteristics.ResultsThe study included 1483 LDV/SOF patients. Mean age was 59.7 years, most were male (63.9%), had commercial insurance (51.9%), and were treatment-naïve (85.6%). Cirrhosis or end stage liver disease was present in 46.1%. Among patients with an expected 8-week treatment regimen, 49.4% were treated for longer. Most patients (99.8%) with expected 12-week treatment durations were adherent to the expected treatment duration. Treatment-experienced patients [odds ratio (OR) 0.124, p < 0.001] and those on Medicare (OR 0.382, p = 0.039) had lower odds of completing the expected treatment regimen, while males were more likely to complete treatment than females (OR 3.235, p = 0.003). SVR12 in patients treated with LDV/SOF was 89.4% (n = 76/85).ConclusionHalf of patients eligible for an 8-week treatment regimen with LDV/SOF were treated longer, while most patients with a 12-week regimen were adherent to the expected treatment duration. Prior HCV treatment, female gender, and Medicare Advantage insurance were associated with lower odds of treatment completion. Overall SVR12 was 89.4%.FundingMerck & Co. Inc. More... »

PAGES

423-433

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40121-017-0163-0

DOI

http://dx.doi.org/10.1007/s40121-017-0163-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090348523

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28677020


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center for Observational and Real-World Evidence, Merck & Co. Inc., Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Center for Observational and Real-World Evidence, Merck & Co. Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puenpatom", 
        "givenName": "Amy", 
        "id": "sg:person.010541612533.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010541612533.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.423532.1", 
          "name": [
            "Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hull", 
        "givenName": "Michael", 
        "id": "sg:person.012703671303.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012703671303.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.423532.1", 
          "name": [
            "Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McPheeters", 
        "givenName": "Jeffrey", 
        "id": "sg:person.012112710301.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012112710301.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.423532.1", 
          "name": [
            "Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwebke", 
        "givenName": "Kay", 
        "id": "sg:person.012463745623.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012463745623.10"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2017-07-04", 
    "datePublishedReg": "2017-07-04", 
    "description": "IntroductionLedipasvir/sofosbuvir (LDV/SOF) for hepatitis C virus (HCV) treatment provides an oral interferon-free treatment regimen with high rates of sustained virologic response (SVR). This study assessed treatment discontinuation, factors associated with treatment completion, and real-world effectiveness.MethodsPatients with HCV treated with LDV/SOF between October 2014 and June 2015 and enrolled in a large US health plan were identified. Expected treatment duration was calculated based on IDSA/AASLD treatment guidelines and US labels using data for genotype, initial treatment regimen, baseline cirrhosis, and prior treatments. Logistic regression was used to identify factors associated with treatment completion, controlling for patient characteristics.ResultsThe study included 1483 LDV/SOF patients. Mean age was 59.7\u00a0years, most were male (63.9%), had commercial insurance (51.9%), and were treatment-na\u00efve (85.6%). Cirrhosis or end stage liver disease was present in 46.1%. Among patients with an expected 8-week treatment regimen, 49.4% were treated for longer. Most patients (99.8%) with expected 12-week treatment durations were adherent to the expected treatment duration. Treatment-experienced patients [odds ratio (OR) 0.124, p\u00a0<\u00a00.001] and those on Medicare (OR 0.382, p\u00a0=\u00a00.039) had lower odds of completing the expected treatment regimen, while males were more likely to complete treatment than females (OR 3.235, p\u00a0=\u00a00.003). SVR12 in patients treated with LDV/SOF was 89.4% (n\u00a0=\u00a076/85).ConclusionHalf of patients eligible for an 8-week treatment regimen with LDV/SOF were treated longer, while most patients with a 12-week regimen were adherent to the expected treatment duration. Prior HCV treatment, female gender, and Medicare Advantage insurance were associated with lower odds of treatment completion. Overall SVR12 was 89.4%.FundingMerck & Co. Inc.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40121-017-0163-0", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1050275", 
        "issn": [
          "2193-8229", 
          "2193-6382"
        ], 
        "name": "Infectious Diseases and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "LDV/SOF", 
      "sustained virologic response", 
      "treatment regimen", 
      "real-world effectiveness", 
      "treatment duration", 
      "treatment completion", 
      "treatment discontinuation", 
      "most patients", 
      "lower odds", 
      "interferon-free treatment regimen", 
      "large US health plan", 
      "end-stage liver disease", 
      "hepatitis C virus (HCV) treatment", 
      "prior HCV treatment", 
      "Medicare Advantage insurance", 
      "ledipasvir/sofosbuvir", 
      "initial treatment regimen", 
      "stage liver disease", 
      "treatment-experienced patients", 
      "C virus treatment", 
      "US health plan", 
      "virologic response", 
      "baseline cirrhosis", 
      "Overall SVR12", 
      "treatment-na\u00efve", 
      "HCV treatment", 
      "patient characteristics", 
      "treatment guidelines", 
      "liver disease", 
      "mean age", 
      "ResultsThe study", 
      "female gender", 
      "regimen", 
      "patients", 
      "virus treatment", 
      "prior treatment", 
      "commercial insurance", 
      "health plans", 
      "logistic regression", 
      "US labels", 
      "SVR12", 
      "cirrhosis", 
      "discontinuation", 
      "sofosbuvir", 
      "treatment", 
      "high rate", 
      "duration", 
      "odds", 
      "MethodsPatients", 
      "HCV", 
      "ConclusionHalf", 
      "SOF", 
      "completion", 
      "adherent", 
      "disease", 
      "adherence", 
      "insurance", 
      "Medicare", 
      "age", 
      "United States", 
      "factors", 
      "males", 
      "study", 
      "females", 
      "guidelines", 
      "gender", 
      "regression", 
      "years", 
      "genotypes", 
      "response", 
      "effectiveness", 
      "rate", 
      "data", 
      "plan", 
      "characteristics", 
      "labels", 
      "state"
    ], 
    "name": "Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States", 
    "pagination": "423-433", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090348523"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40121-017-0163-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28677020"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40121-017-0163-0", 
      "https://app.dimensions.ai/details/publication/pub.1090348523"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_745.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40121-017-0163-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0163-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0163-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0163-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0163-0'


 

This table displays all metadata directly associated to this object as RDF triples.

162 TRIPLES      20 PREDICATES      102 URIs      94 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40121-017-0163-0 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author Na29e1f2ab48e400d8ab7f9cb0e877c6e
4 schema:datePublished 2017-07-04
5 schema:datePublishedReg 2017-07-04
6 schema:description IntroductionLedipasvir/sofosbuvir (LDV/SOF) for hepatitis C virus (HCV) treatment provides an oral interferon-free treatment regimen with high rates of sustained virologic response (SVR). This study assessed treatment discontinuation, factors associated with treatment completion, and real-world effectiveness.MethodsPatients with HCV treated with LDV/SOF between October 2014 and June 2015 and enrolled in a large US health plan were identified. Expected treatment duration was calculated based on IDSA/AASLD treatment guidelines and US labels using data for genotype, initial treatment regimen, baseline cirrhosis, and prior treatments. Logistic regression was used to identify factors associated with treatment completion, controlling for patient characteristics.ResultsThe study included 1483 LDV/SOF patients. Mean age was 59.7 years, most were male (63.9%), had commercial insurance (51.9%), and were treatment-naïve (85.6%). Cirrhosis or end stage liver disease was present in 46.1%. Among patients with an expected 8-week treatment regimen, 49.4% were treated for longer. Most patients (99.8%) with expected 12-week treatment durations were adherent to the expected treatment duration. Treatment-experienced patients [odds ratio (OR) 0.124, p < 0.001] and those on Medicare (OR 0.382, p = 0.039) had lower odds of completing the expected treatment regimen, while males were more likely to complete treatment than females (OR 3.235, p = 0.003). SVR12 in patients treated with LDV/SOF was 89.4% (n = 76/85).ConclusionHalf of patients eligible for an 8-week treatment regimen with LDV/SOF were treated longer, while most patients with a 12-week regimen were adherent to the expected treatment duration. Prior HCV treatment, female gender, and Medicare Advantage insurance were associated with lower odds of treatment completion. Overall SVR12 was 89.4%.FundingMerck & Co. Inc.
7 schema:genre article
8 schema:isAccessibleForFree true
9 schema:isPartOf Na35bf218ad7c4d1aaf4b2d20ab864461
10 Nf320052a35ab4e7693d7cf1a8ebf3c7d
11 sg:journal.1050275
12 schema:keywords C virus treatment
13 ConclusionHalf
14 HCV
15 HCV treatment
16 LDV/SOF
17 Medicare
18 Medicare Advantage insurance
19 MethodsPatients
20 Overall SVR12
21 ResultsThe study
22 SOF
23 SVR12
24 US health plan
25 US labels
26 United States
27 adherence
28 adherent
29 age
30 baseline cirrhosis
31 characteristics
32 cirrhosis
33 commercial insurance
34 completion
35 data
36 discontinuation
37 disease
38 duration
39 effectiveness
40 end-stage liver disease
41 factors
42 female gender
43 females
44 gender
45 genotypes
46 guidelines
47 health plans
48 hepatitis C virus (HCV) treatment
49 high rate
50 initial treatment regimen
51 insurance
52 interferon-free treatment regimen
53 labels
54 large US health plan
55 ledipasvir/sofosbuvir
56 liver disease
57 logistic regression
58 lower odds
59 males
60 mean age
61 most patients
62 odds
63 patient characteristics
64 patients
65 plan
66 prior HCV treatment
67 prior treatment
68 rate
69 real-world effectiveness
70 regimen
71 regression
72 response
73 sofosbuvir
74 stage liver disease
75 state
76 study
77 sustained virologic response
78 treatment
79 treatment completion
80 treatment discontinuation
81 treatment duration
82 treatment guidelines
83 treatment regimen
84 treatment-experienced patients
85 treatment-naïve
86 virologic response
87 virus treatment
88 years
89 schema:name Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
90 schema:pagination 423-433
91 schema:productId Ncc48c9cc9d22460980b732252b1f0708
92 Nd33d660014904332846890741b8db3a0
93 Nefabd0fb6f634f69a6e37821a9155249
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090348523
95 https://doi.org/10.1007/s40121-017-0163-0
96 schema:sdDatePublished 2022-12-01T06:36
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N517b312add6740fc882461455d1e917e
99 schema:url https://doi.org/10.1007/s40121-017-0163-0
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N4e280629b0da4f74b39a25fc61b2e5b9 rdf:first sg:person.012463745623.10
104 rdf:rest rdf:nil
105 N517b312add6740fc882461455d1e917e schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 Na29e1f2ab48e400d8ab7f9cb0e877c6e rdf:first sg:person.010541612533.82
108 rdf:rest Ncbac543f5ba248f19ed24d4e1734a1bc
109 Na35bf218ad7c4d1aaf4b2d20ab864461 schema:volumeNumber 6
110 rdf:type schema:PublicationVolume
111 Ncbac543f5ba248f19ed24d4e1734a1bc rdf:first sg:person.012703671303.45
112 rdf:rest Nfe918ea6dd9e4b8aabac5776723426d1
113 Ncc48c9cc9d22460980b732252b1f0708 schema:name pubmed_id
114 schema:value 28677020
115 rdf:type schema:PropertyValue
116 Nd33d660014904332846890741b8db3a0 schema:name doi
117 schema:value 10.1007/s40121-017-0163-0
118 rdf:type schema:PropertyValue
119 Nefabd0fb6f634f69a6e37821a9155249 schema:name dimensions_id
120 schema:value pub.1090348523
121 rdf:type schema:PropertyValue
122 Nf320052a35ab4e7693d7cf1a8ebf3c7d schema:issueNumber 3
123 rdf:type schema:PublicationIssue
124 Nfe918ea6dd9e4b8aabac5776723426d1 rdf:first sg:person.012112710301.76
125 rdf:rest N4e280629b0da4f74b39a25fc61b2e5b9
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
130 schema:name Public Health and Health Services
131 rdf:type schema:DefinedTerm
132 sg:journal.1050275 schema:issn 2193-6382
133 2193-8229
134 schema:name Infectious Diseases and Therapy
135 schema:publisher Springer Nature
136 rdf:type schema:Periodical
137 sg:person.010541612533.82 schema:affiliation grid-institutes:grid.417993.1
138 schema:familyName Puenpatom
139 schema:givenName Amy
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010541612533.82
141 rdf:type schema:Person
142 sg:person.012112710301.76 schema:affiliation grid-institutes:grid.423532.1
143 schema:familyName McPheeters
144 schema:givenName Jeffrey
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012112710301.76
146 rdf:type schema:Person
147 sg:person.012463745623.10 schema:affiliation grid-institutes:grid.423532.1
148 schema:familyName Schwebke
149 schema:givenName Kay
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012463745623.10
151 rdf:type schema:Person
152 sg:person.012703671303.45 schema:affiliation grid-institutes:grid.423532.1
153 schema:familyName Hull
154 schema:givenName Michael
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012703671303.45
156 rdf:type schema:Person
157 grid-institutes:grid.417993.1 schema:alternateName Center for Observational and Real-World Evidence, Merck & Co. Inc., Kenilworth, NJ, USA
158 schema:name Center for Observational and Real-World Evidence, Merck & Co. Inc., Kenilworth, NJ, USA
159 rdf:type schema:Organization
160 grid-institutes:grid.423532.1 schema:alternateName Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA
161 schema:name Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA
162 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...